A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Status:
Unknown status
Trial end date:
2021-08-20
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the tolerability, safety and efficacy of SHR-1210 in
combination with Apatinib and Fluzoparib in subjects with recurrent and metastatic triple
negative breast cancer